Genmab A/S (GNMSF) — SEC Filings
Genmab A/S (GNMSF) — 50 SEC filings. Latest: 6-K (Dec 29, 2025). Includes 50 6-K.
Overview
Genmab A/S (GNMSF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 29, 2025: Genmab A/S filed a Form 6-K on December 29, 2025, to report company announcements. This filing is incorporated by reference into several of Genmab's existing S-8 registration statements, including File Nos. 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 7 bullish, 43 neutral. The dominant filing sentiment for Genmab A/S is neutral.
Filing Type Overview
Genmab A/S (GNMSF) has filed 50 6-K with the SEC between Mar 2025 to Dec 2025.
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of GNMSF's 48 recent filings, 0 were flagged as high-risk, 2 as medium-risk, and 46 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Top Tags
sec-filing (14) · share-buyback (10) · registration-statement (8) · regulatory-filing (8) · disclosure (7) · corporate-governance (6) · reporting (6) · capital-return (5) · filing (4) · stock-options (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Acquisition Value | $1.5B | Genmab's proposed purchase price for Merus. |
| Capital Increase | DKK 1.1 million | Resulting from employee warrant exercise on September 9, 2025. |
| Capital Increase (USD) | USD 0.16 million | Equivalent amount in US dollars. |
| Share Buy-back Cost | DKK 230.0M | Total amount spent by Genmab on repurchasing shares. |
| Shares Repurchased | 1.0M | Number of Genmab shares bought back as part of the program. |
| Share Buy-back Value | DKK 2.5B | Total amount spent on repurchasing shares. |
| Average Share Price | DKK 2,500 | Average price paid per share during the buy-back. |
| Shares Purchased | 1,000,000 | Part of the share buy-back program |
| Total Buy-back Value | DKK 2.4 billion | Represents capital returned to shareholders |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Genmab A/S (GNMSF)?
Genmab A/S has 50 recent SEC filings from Mar 2025 to Dec 2025, including 50 6-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GNMSF filings?
Across 50 filings, the sentiment breakdown is: 7 bullish, 43 neutral. The dominant sentiment is neutral.
Where can I find Genmab A/S SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Genmab A/S (GNMSF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Genmab A/S?
Financial highlights for Genmab A/S are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for GNMSF?
Investment thesis data for GNMSF will be available once enriched filings are processed.
Who are the key executives at Genmab A/S?
Executive information for Genmab A/S is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Genmab A/S stock?
Of GNMSF's 48 assessed filings, 0 were flagged high-risk, 2 medium-risk, and 46 low-risk.
What are recent predictions and forward guidance from Genmab A/S?
Forward guidance and predictions for Genmab A/S are extracted from SEC filings as they are enriched.